Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 3 EP applications Elizabeth Mary Morters has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after December 15, 2012). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12727669

TUMOUR NECROSIS FACTOR RECEPTOR 1 ANTAGONISTS

IPC classification:
A61K 39/395, C07K 16/28
Applicant:
Glaxo Group Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP12744272

CATHEPSIN C INHIBITORS

IPC classification:
A01N 43/16, A61K 31/35, C07D 309/14, C07D 405/12
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
NO OPPOSITION FILED WITHIN TIMELIMIT
EP11831214

BENZIMIDAZOLE DERIVATIVES AS PI3 KINASE INHIBITORS

IPC classification:
A01N 43/52, A61K 31/4164, C07D 235/08, C07D 235/10, C07D 235/24, C07D 401/10, C07D 403/04, C07D 403/10, C07D 405/04, C07D 405/10, C07D 409/10, C07D 413/04, C07D 413/10, C07D 417/04, C07D 417/10, C07D 513/04
Applicant:
GlaxoSmithKline LLC
Agent:
Multiple attorneys, GlaxoSmithKline
Status:
PATENT GRANTED

Please Sign in to use this feature